| Nathaniel Weatherby Miller, MD | |
|
Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 | |
| (050) 333-7411 | |
| Not Available |
| Full Name | Nathaniel Weatherby Miller |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Location | Brian D. Allgood Army Community Hospital (bdaach), Apo, Armed Forces Pacific |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225527450 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 0101267719 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nathaniel Weatherby Miller, MD Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Ph: () - | Nathaniel Weatherby Miller, MD Brian D. Allgood Army Community Hospital (bdaach), Unit #15245; Bldg 3031, Apo, AP 96271 Ph: (050) 333-7411 |
News Archive
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.
Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.
The team of Bruno Giros, a researcher at the Douglas Mental Health University Institute and professor of psychiatry at McGill University, reports the first-ever connection between noradrenergic neurons and vulnerability to depression. Published in the journal Nature Neuroscience, this breakthrough paves the way for new depression treatments that target the adrenergic system.
As the brain has limited capability for self-repair or regeneration, stem cells may represent the best therapeutic approach for counteracting damage to or degeneration of brain tissue caused by injury, aging, or disease.
› Verified 6 days ago
Jeremy Nielsen Rich, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Baach, 121 Csh, Otolaryngology Section, Apo, AP 96205 Phone: 315-737-1285 |